FAM172A expression in circulating tumor cells for prediction of high-risk subgroups of colorectal cancer
Authors Xu C, Zhang C, Wang H, Yang H, Li G, Fei Z, Li W
Received 28 July 2016
Accepted for publication 5 November 2016
Published 30 March 2017 Volume 2017:10 Pages 1933—1939
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Amy Norman
Peer reviewer comments 4
Editor who approved publication: Dr Samir Farghaly
This paper has been Retracted
Chang Xu,1 Chunhong Zhang,2 Haowen Wang,3 Han Yang,3 Gang Li,3 Zhenghua Fei,3 Wenfeng Li1,3,4
1Department of Colorectal Surgery, 2Department of Pharmacy, 3Department of Chemoradiotherapy, 4Laboratory for Interdisciplinary Research, Institution for Translational Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, People’s Republic of China
Objectives: Previous studies used enumerated circulating tumor cells (CTCs) to predict prognosis and therapeutic effect in several types of cancers. However, increasing evidence showed that only enumerated CTCs were not enough to reflect the heterogeneity of tumors. Therefore, we classified different metastasis potentials of CTCs from colorectal cancer (CRC) patients to improve the accuracy of prognosis by CTCs.
Methods: Blood samples were collected from 45 primary CRC patients. CTCs were enriched by blood filtration, and the RNA in situ hybridization method was used to identify and discriminate subgroups of CTCs. Later, FAM172A expression in individual CTCs was measured.
Results: Three CTC subgroups (epithelial/biophenotypic/mesenchymal CTCs) were identified using epithelial–mesenchymal transition markers. In our research, mesenchymal CTCs significantly increased along with tumor progression, including developing distant metastasis and vascular invasion. Furthermore, FAM172A expression rate in mesenchymal CTCs was significantly higher than that in epithelial CTCs, which suggested that FAM172A may correlate with tumor malignancy. This hypothesis was further verified by FAM172A expression in mesenchymal CTCs strictly related to tumor aggressiveness factors. Finally, we revealed that mesenchymal CTCs and FAM172A expression may predict high-risk subgroups in stage II CRC.
Conclusion: Our research proved that CTCs could serve as feasible surrogate samples to detect gene expression as a predictive biomarker for tumor evaluation.
Keywords: colorectal cancer, circulating tumor cells, epithelial–mesenchymal transition, FAM172A
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]